Isabelle Sermet-Gaudelus Selected Research

Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)

12/2022	Systemic bis-phosphinic acid derivative restores chloride transport in Cystic Fibrosis mice.
1/2022	Correlating genotype with phenotype using CFTR-mediated whole-cell Cl- currents in human nasal epithelial cells.
1/2022	Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR.
11/2021	Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension.
11/2021	Therapeutic pipeline for individuals with cystic fibrosis with mutations nonresponsive to current cystic fibrosis transmembrane conductance regulator modulators.
1/2021	Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis.
1/2021	Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID).
1/2020	Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis.
1/2019	Airway surface liquid acidification initiates host defense abnormalities in Cystic Fibrosis.
1/2019	Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Isabelle Sermet-Gaudelus Research Topics

Disease

62	Cystic Fibrosis (Mucoviscidosis) 12/2022 - 01/2002
11	Inflammation (Inflammations) 12/2022 - 10/2005
8	Infections 01/2021 - 01/2002
5	Inborn Genetic Diseases (Disease, Hereditary) 01/2022 - 10/2005
5	Lung Diseases (Lung Disease) 01/2020 - 05/2007
4	Bone Diseases (Bone Disease) 11/2016 - 03/2014
2	Cough 01/2021 - 10/2010
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2021 - 02/2017
2	Vitamin K Deficiency 11/2019 - 09/2009
2	Malnutrition (Nutritional Deficiencies) 11/2019 - 09/2009
2	Metabolic Bone Diseases (Osteopenia) 10/2019 - 04/2016
2	Bone Resorption 11/2016 - 01/2010
2	Persistent Infection 12/2011 - 05/2011
2	Bronchiectasis 05/2010 - 01/2008
1	Respiratory Insufficiency (Respiratory Failure) 12/2022
1	Liver Diseases (Liver Disease) 01/2022
1	Hypoxia (Hypoxemia) 11/2021
1	Pulmonary Hypertension 11/2021
1	Coronavirus Infections 01/2021
1	Vasculitis (Vasculitides) 01/2021
1	Primary Headache Disorders 01/2021
1	Kidney Diseases (Kidney Disease) 09/2020
1	Clinical Deterioration 01/2020
1	Intestinal Obstruction (Obstruction, Intestinal) 12/2019
1	Osteoporosis 10/2019
1	Hypogonadism (Hypergonadotropic Hypogonadism) 10/2019
1	Hyperplasia 10/2018
1	Airway Obstruction (Choking) 10/2018
1	Bacterial Infections (Bacterial Infection) 10/2018
1	Drug Eruptions (Drug Eruption) 01/2018
1	Allergic Bronchopulmonary Aspergillosis 12/2017
1	Hypersensitivity (Allergy) 12/2017
1	Asthma (Bronchial Asthma) 12/2017
1	Intestinal Fistula 01/2017
1	Chronic Kidney Failure (Chronic Renal Failure) 12/2016
1	Vitamin D Deficiency 12/2016
1	Human Influenza (Influenza) 02/2016
1	Ciliary Motility Disorders (Primary Ciliary Dyskinesia) 01/2016

Drug/Important Bio-Agent (IBA)

25	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 12/2022 - 11/2003
11	ivacaftorIBA 01/2022 - 11/2011
11	Proteins (Proteins, Gene)FDA Link 12/2021 - 11/2002
8	ChloridesIBA 12/2022 - 05/2005
5	Chloride Channels (Chloride Channel)IBA 11/2021 - 10/2005
5	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 01/2002
5	Vitamin D FDA LinkGeneric 11/2019 - 05/2007
4	Nonsense Codon (Nonsense Mutation)IBA 01/2018 - 11/2010
3	lumacaftorIBA 01/2022 - 01/2020
3	Cyclic AMP (AMP, Cyclic)IBA 07/2016 - 10/2006
3	Tobramycin (Nebcin)FDA LinkGeneric 07/2014 - 01/2002
2	ivacaftor drug combination tezacaftorIBA 01/2022 - 01/2021
2	AnionsIBA 01/2022 - 11/2018
2	ivacaftor drug combination lumacaftorIBA 01/2021 - 01/2019
2	Antisense OligonucleotidesIBA 01/2021 - 01/2019
2	Pharmaceutical PreparationsIBA 01/2021 - 11/2014
2	Gonadal Steroid Hormones (Sex Hormones)IBA 11/2019 - 09/2009
2	GlucocorticoidsIBA 11/2019 - 09/2009
2	CalciumIBA 10/2019 - 12/2016
2	Ceftazidime (Fortum)FDA LinkGeneric 01/2018 - 09/2009
2	Phosphorus (Red Phosphorus)IBA 12/2016 - 07/2014
2	Biological ProductsIBA 01/2015 - 07/2014
2	atalurenIBA 07/2014 - 11/2010
2	LipidsIBA 05/2011 - 11/2009
2	neodymium pyrocatechin disulfonate (NPD)IBA 10/2010 - 08/2004
1	Phosphinic Acids (Phosphinic Acid)IBA 12/2022
1	Amino Acids FDA Link 12/2022
1	Ion Channels (Ion Channel)IBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	MonocrotalineIBA 11/2021
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 11/2021
1	trans-crotonin (CTN)IBA 11/2021
1	AntibodiesIBA 01/2021
1	tezacaftorIBA 01/2021
1	Drug CombinationsIBA 01/2021
1	LaxativesIBA 12/2019
1	Diphosphonates (Bisphosphonates)IBA 10/2019
1	VitaminsIBA 10/2019
1	eluforsenIBA 01/2019
1	Protons (Proton)IBA 10/2018
1	CytokinesIBA 10/2018
1	Proton Pumps (Proton Pump)IBA 10/2018
1	Interleukin-4 (Interleukin 4)IBA 10/2018
1	Peptide Hydrolases (Proteases)FDA Link 01/2018
1	resolvin D1IBA 01/2018
1	AllergensIBA 12/2017
1	Omalizumab (Xolair)FDA Link 12/2017
1	anti-IgE antibodiesIBA 12/2017
1	TrypsinogenIBA 02/2017
1	RANK LigandIBA 11/2016
1	NucleotidesIBA 07/2016
1	LigandsIBA 07/2016
1	Phospholipases A2 (Phospholipase A2)IBA 07/2016
1	Keratin-8 (Keratin 8)IBA 04/2016
1	Oseltamivir (Tamiflu)FDA Link 02/2016
1	Dyneins (Dynein)IBA 01/2016

Therapy/Procedure

14	Therapeutics 01/2021 - 09/2009
2	Terminal Care (Care, Terminal) 01/2018 - 05/2014
1	Transplantation 01/2021
1	Microelectrodes 01/2019
1	Ileostomy 01/2017
1	Lung Transplantation 02/2016